Esperion Therapeutics, Inc. - Common Stock (ESPR)

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Esperion Therapeutics (ESPR) beats Q2 2025 revenue estimates with $82.4M, narrows losses, and sees 42% U.S. sales growth. Stock surges 12% pre-market.

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.

CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key markets.

ESPR stock results show that Esperion Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024.

Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy.

These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential.